(CercleFinance.com) – Pfizer today announced positive results from a Phase 3 study of etrasimod as a potential treatment for moderate to severe active ulcerative colitis (UC).
In this 52-week study, patients receiving etrasimod achieved statistically significant improvements in the primary endpoints of clinical remission at weeks 12 and 52 compared to placebo.
“These data underscore the potential of etrasimod as a first-line therapy in patients with moderate to severe ulcerative colitis, should it be approved,” summarizes Michael Corbo, director of development, Inflammation and Immunology at Pfizer. Global Product Development.
Full study results will be submitted for future scientific publication and presentation.
Pfizer recalls that Etrasimod was developed by Arena Pharmaceuticals, before being recently acquired by Pfizer.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
